{"filing":{"accession_number":"0001654954-26-007679","cik":"0000901832","ticker":"AZN","company_name":"ASTRAZENECA PLC","form":"6-K","filing_date":"2026-08-17","report_date":"2026-08-17","primary_document":"a8439q.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/901832/000165495426007679/a8439q.htm"},"events":[{"id":28088,"run_id":25672,"accession_number":"0001654954-26-007679","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"AstraZeneca announced discontinuation of the eVOLVE-Lung02 Phase III trial of volrustomig based on an Independent Data Monitoring Committee recommendation that the drug combination was unlikely to meet dual primary endpoints (PFS and OS) in the primary analysis population. This is a material clinical development setback affecting a late-stage oncology program, but does not fit the specific event categories (not an earnings release, impairment charge, or litigation). It is clearly operational—a strategic decision to halt a clinical trial—making operational_other the appropriate classification.","company_name":"ASTRAZENECA PLC","ticker":"AZN","filing_date":"2026-08-17","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":29893,"accession_number":"0001654954-26-007679","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"AstraZeneca announced discontinuation of the eVOLVE-Lung02 Phase III trial of volrustomig based on an Independent Data Monitoring Committee recommendation that the drug combination was unlikely to meet dual primary endpoints (PFS and OS) in the primary analysis population. This is a material clinical development setback affecting a late-stage oncology program, but does not fit the specific event categories (not an earnings release, impairment charge, or litigation). It is clearly operational—a strategic decision to halt a clinical trial—making operational_other the appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-17T11:57:04.724527+00:00","company_name":"ASTRAZENECA PLC","ticker":"AZN","filing_date":"2026-08-17"}]}